Low Risk vs High Risk MDS - What's the Difference?

In this webinar, Dr. Marlise Luskin from Dana Farber Cancer Institute will define high-risk MDS versus low-risk MDS, impact for patients and what treatment options are available.

This webinar is brought to you by the generous support of Celgene, Takeda and Jazz Pharmaceuticals.

• #nonprofits_activism
• #low_risk_mds
• #high_risk_mds
• #myelodysplastic_syndromes
• #myelodysplasia
• #mds_treatments
• #mds_genetics
• #mds_markers
• #mds_scoring
• #aamdsif